Basic Information
| LncRNA/CircRNA Name | LINC-PINT |
| Synonyms | LINC-PINT, LincRNA-Pint, MKLN1-AS1, PINT |
| Region | GRCh38_7:130938963-131110176 |
| Ensemble | ENSG00000231721 |
| Refseq | NR_015431 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR etc. |
| Sample | prostate cancer tissues, cell lines (WPMY-1, DU145, PC-3 and LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | To further validate the results, we examined the expression levels in 11 normal prostate tissues and 14 prostate cancer tissues with real-time PCR. All of these lncRNAs except LINC00969, were expressed significantly higher in prostate cancer samples compared with normal prostate tissues, which were consistent with the TCGA and microarray results. Then, the expression levels of ten lncRNAs were validated in the noncancerous prostatic cells WPMY-1 and four human prostate cancer cell lines by qRT-PCR. It turned out that most of the ten lncRNAs were up-regulated in prostate cancer cell lines and showed a similar expression pattern in patient samples. |
| Pubmed ID | 27556357 |
| Year | 2016 |
| Title | Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. |
External Links
| Links for LINC-PINT | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |